Klivira
Request demo

Xultophy Prior Authorization for Oncology Patients

For oncology practices managing complex patient needs, securing Xultophy prior authorization for oncology patients requires a streamlined approach to comorbidity management within cancer care workflows.

Oncology patients frequently present with multiple comorbidities, including diabetes, necessitating medications like Xultophy. While not an oncology therapeutic, prior authorization for these essential supportive medications adds significant administrative burden. Klivira helps integrate these diverse PA requirements into a unified, efficient process, ensuring comprehensive patient care without compromising treatment timelines.

Xultophy in the Oncology Patient Journey

Xultophy, a combination of insulin degludec and liraglutide, is a high-volume prior authorization target primarily for diabetes management across commercial, Medicare Advantage, and Medicaid managed care plans. In oncology, its use is typically for managing pre-existing or treatment-induced diabetes in cancer patients. Integrating the prior authorization for such comorbidity medications into the intricate oncology PA workflow is crucial for holistic patient care and preventing treatment delays.

Navigating Prior Authorization for Comorbidity Management in Oncology

Oncology practices face unique PA complexities, including high-cost biologics, infusion therapy, radiation oncology, and frequent regimen changes. When a cancer patient requires a medication like Xultophy for a comorbidity, its prior authorization must align with the broader cancer care plan. Klivira's platform is designed to manage the concurrent PA events for both primary oncology treatments and essential supportive care or comorbidity medications, streamlining submissions and tracking across all patient needs.

Common Documentation for Supportive Care and Comorbidity PAs in Oncology

  • Patient's confirmed oncology diagnosis and treatment plan to demonstrate medical necessity for overall care.
  • Documentation of diabetes diagnosis (e.g., A1c levels, blood glucose readings) and rationale for Xultophy selection.
  • Evidence of prior-line diabetes treatment failures or contraindications, if step therapy applies.
  • Overall performance status (e.g., ECOG or Karnofsky score) and comorbidity burden.
  • Relevant lab results (e.g., renal function, liver function) to support appropriate dosing and safety.

Addressing Denial Reasons for Non-Oncology Medications in Cancer Care

Denials for medications like Xultophy in oncology patients often stem from issues common to other supportive care PAs. These can include step therapy requirements for diabetes medications, documentation gaps regarding comorbidity severity or prior treatment history, or site-of-service mismatches if the drug is administered in an unexpected setting. Klivira's system helps identify potential denial risks pre-submission, ensuring comprehensive data capture and adherence to payer policies for both oncology and non-oncology drugs.

Klivira's Integrated Approach to Oncology Prior Authorization

Klivira's platform provides a comprehensive solution for oncology practices, extending beyond primary cancer therapeutics to include medications for comorbidities like Xultophy. Our system leverages NCCN-compendium-aware logic for oncology-specific drugs and integrates with payer portals and PBMs for all medication types. This ensures seamless routing for medical benefit (J-coded infusions) and pharmacy benefit (oral oncolytics, supportive care) drugs, reducing administrative burden and accelerating time to therapy for the entire patient regimen.

Frequently asked questions

Is Xultophy considered an oncology drug for prior authorization purposes?

No, Xultophy is a medication for diabetes management. However, when prescribed to an oncology patient, its prior authorization process becomes part of the broader administrative workflow for cancer care. Klivira's platform manages PAs for both primary oncology treatments and essential supportive care medications like Xultophy.

How does Klivira handle Xultophy PA when managing multiple oncology PAs for a single patient?

Klivira's platform supports concurrent PA tracking, allowing practices to manage dozens of PA events per patient across their entire treatment course. This includes primary oncology regimens, supportive care, imaging, and comorbidity medications like Xultophy, streamlining submissions and monitoring their status simultaneously.

What specific documentation is needed for Xultophy PA in an oncology setting?

Key documentation for Xultophy PA in an oncology setting includes the patient's diabetes diagnosis, rationale for Xultophy, prior treatment history, and relevant lab work. While NCCN guidelines govern oncology therapeutics, the PA for Xultophy would follow standard diabetes management criteria, integrated within the patient's overall oncology medical record.

Are there specific NCCN guidelines for Xultophy in oncology patients?

NCCN Clinical Practice Guidelines primarily focus on cancer treatment and management. While NCCN may address diabetes as a comorbidity, specific guidelines for Xultophy use in oncology patients are not typically found within the NCCN Compendium. Prior authorization for Xultophy relies on general medical necessity criteria for diabetes treatment.

How does the medical vs. pharmacy benefit split affect Xultophy PA for oncology patients?

Xultophy is typically a pharmacy benefit drug. Its prior authorization would route through the payer's PBM and ePA partners (e.g., CoverMyMeds, Surescripts), distinct from medical benefit PAs for provider-administered oncology infusions (which route via X12 278 or payer portals). Klivira's system intelligently routes each PA request to the correct channel based on the drug's benefit classification.

Related coverage

Other xultophy prior authorization by payer

Other xultophy prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo